What is the recommended treatment for a urinary tract infection (UTI)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Urinary Tract Infections

Uncomplicated Cystitis in Women

For uncomplicated cystitis in otherwise healthy, non-pregnant women, nitrofurantoin (100 mg twice daily for 5 days) is the preferred first-line treatment, with trimethoprim-sulfamethoxazole (160/800 mg twice daily for 3 days) and fosfomycin (3 g single dose) as alternatives. 1, 2

First-Line Antibiotic Options

  • Nitrofurantoin: 100 mg twice daily for 5 days is the drug of choice because it spares more systemically active agents, has low resistance rates, and resistance decays quickly even when present 1, 2

  • Fosfomycin trometamol: 3 g single oral dose provides convenient single-dose therapy with minimal resistance 1, 2, 3

  • Trimethoprim-sulfamethoxazole (TMP-SMX): 160/800 mg twice daily for 3 days, but only use if local resistance rates are <20% 1, 2, 3

  • Pivmecillinam: 3 days where available 1

Second-Line Options

  • Amoxicillin-clavulanate can be used as an alternative, particularly in young children, though it was removed from WHO first-line recommendations in 2021 due to high resistance rates (median 75% of E. coli resistant to amoxicillin alone) 1

  • Fluoroquinolones should NOT be used as first-line therapy due to increasing resistance, serious adverse effects (tendon, muscle, joint, nerve, and CNS toxicity), and the FDA's 2016 warning that the risks outweigh benefits for uncomplicated UTI 1, 2

Treatment Duration

  • Nitrofurantoin: 5 days 1, 2
  • TMP-SMX: 3 days 1, 2
  • Fosfomycin: Single dose 1, 2
  • Fluoroquinolones (if used): 3 days 1
  • Pivmecillinam: 3 days 1

Acute Pyelonephritis

For acute pyelonephritis requiring oral therapy, TMP-SMX or first-generation cephalosporins are reasonable first-line agents if local resistance rates permit; for patients requiring intravenous therapy, ceftriaxone is the recommended empirical choice. 1, 2

Treatment Options

  • Oral therapy: TMP-SMX or first-generation cephalosporins, depending on local resistance patterns 1

  • Intravenous therapy: Ceftriaxone is preferred due to low resistance rates and clinical effectiveness, unless risk factors for multidrug resistance exist 1

  • Ciprofloxacin can be used as first-line for mild-to-moderate pyelonephritis only if local/national antimicrobial resistance data support its use (resistance should be <10%) 1

  • Severe cases: Amikacin (preferred over gentamicin), ceftriaxone, or cefotaxime 1

Treatment Duration

  • Beta-lactams: 7 days 1
  • Fluoroquinolones: 5-7 days 1
  • TMP-SMX: Insufficient evidence for clear duration recommendation 1

Do NOT use nitrofurantoin for pyelonephritis as it does not achieve adequate tissue concentrations 2

Uncomplicated UTI in Men

Men with uncomplicated UTI should receive trimethoprim, TMP-SMX, or nitrofurantoin for 7 days (longer than women), and always obtain urine culture to guide therapy. 2, 3

  • Treatment duration is 7 days for men (versus 3-5 days for women with cystitis) 2
  • Consider urethritis and prostatitis as alternative diagnoses 3
  • Urine culture with susceptibility testing should always be obtained 3

Critical Diagnostic and Treatment Principles

When to Obtain Urine Culture

Obtain urine culture before treatment in: 2

  • Suspected pyelonephritis
  • Symptoms persisting >4 weeks after treatment
  • Atypical symptoms
  • Recurrent UTIs
  • Pregnant women
  • All men with UTI symptoms 3

What NOT to Do

  • Do NOT treat asymptomatic bacteriuria except in pregnant women and patients scheduled for urologic procedures 2

  • Do NOT classify recurrent UTI patients as "complicated" as this leads to unnecessary broad-spectrum antibiotics; reserve "complicated" for structural/functional urinary tract abnormalities, immunosuppression, or pregnancy 1

  • Do NOT use single-dose antibiotics (except fosfomycin) due to higher bacteriological persistence rates 2

  • Do NOT obtain routine post-treatment urine cultures in asymptomatic patients 2

  • Do NOT use fluoroquinolones as first-line therapy due to serious adverse effects and the need for antimicrobial stewardship 1, 2

Empiric Treatment Selection Framework

When selecting empiric therapy, consider: 1

  • Local resistance patterns (antibiograms)
  • Prior culture results if available
  • Patient allergies and prior adverse effects
  • Risk factors for antimicrobial resistance
  • Clinical severity
  • Cost considerations

Special Considerations for Resistance

  • Nitrofurantoin resistance decays rapidly: only 20.2% at 3 months and 5.7% at 9 months, with initial prevalence of only 2.6% 1

  • Fluoroquinolones and cephalosporins cause more collateral damage to fecal microbiota and increase C. difficile risk compared to other antibiotic classes 1

  • Beta-lactam antibiotics promote more rapid UTI recurrence due to disruption of protective periurethral and vaginal microbiota 1

Recurrent UTI Prevention

For patients with recurrent UTI (>2 culture-positive UTIs in 6 months or >3 in one year): 1

Postmenopausal Women

  • Vaginal estrogen with or without lactobacillus-containing probiotics 1

Premenopausal Women with Post-Coital Infections

  • Low-dose post-coital antibiotics within 2 hours of sexual activity for 6-12 months 1
  • Preferred agents: nitrofurantoin 50 mg, TMP-SMX 40/200 mg, or trimethoprim 100 mg 1

Non-Antibiotic Alternatives

  • Methenamine hippurate and/or lactobacillus-containing probiotics 1, 3
  • Cranberry products for prevention 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Urinary Tract Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.